SCHEMBL13342797

SCHEMBL13342797

Cc1cc(Cl)ccc1OC(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN4A P35499 2/20 0.60
▸ MAPT P10636 3/20 0.49
▸ MRGPRX4 Q96LA9 1/20 0.48
▸ PPARA Q07869 4/20 0.48
▸ TSHR P16473 1/20 0.47
▸ HTR2A P28223 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PPARG P37231 2/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ALPI P09923 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ XIAP P98170 1/20 0.45
▸ SLC7A5 Q01650 1/20 0.45
▸ OPRM1 P35372 1/20 0.45
▸ OPRD1 P41143 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13342811 0.83 SCN4A (0.47) SCN4AMAPTLMNAOPRM1OPRD1
SCHEMBL13342804 0.82 NPSR1 (0.50) SCN4AMAPTMRGPRX4TSHRHTR2A
SCHEMBL13342825 0.81 SCN4A (0.48) SCN4AMAPTLMNATP53HTT
SCHEMBL13342824 0.81 PSMB5 (0.48) SCN4AMAPTLMNAOPRM1OPRD1
SCHEMBL13342793 0.80 TSHR (0.50) SCN4AMAPTTSHRHTR2AHTR2C
SCHEMBL13342757 0.80 SMN1; SMN2 (0.55) SCN4AMAPTMRGPRX4PPARATSHR
SCHEMBL13342807 0.78 MEN1 (0.45) SCN4AMAPTTSHRHTR2AHTR2C
SCHEMBL13342871 0.77 PYGL (0.54) SCN4AL3MBTL1CYP2C9ALDH1A1
SCHEMBL13342767 0.77 MRGPRX4 (0.51) SCN4AMAPTMRGPRX4TSHRHTR2A
SCHEMBL12740369 0.76 SCN4A (0.49) SCN4APPARAPPARGL3MBTL1ALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 — — US disclosed
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 — — US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 — — US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES RELA, NFKBIA, NFE2 SCN4A 1587/4885MAPT 4188/4885MRGPRX4 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback